PersImmune

Pers Immune

Biotechnology, Sorrento Valley Rd, San Diego, , 92121, California, 11555, United States, 1-10 Employees

persimmune.com

  • twitter
  • LinkedIn

phone no Phone Number: 85********

Who is PERSIMMUNE

PersImmune is a clinical-stage immunotherapy company whose mission is to provide cancer patients with optimized immunotherapy that is personalized on the basis of their own unique tumor s...

Read More

map
  • 11555 Sorrento Valley Rd, San Diego, California, 92121, United States Headquarters: 11555 Sorrento Valley Rd, San Diego, California, 92121, United States
  • 2009 Date Founded: 2009
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from PERSIMMUNE

PersImmune Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding PersImmune

Answer: PersImmune's headquarters are located at Sorrento Valley Rd, San Diego, , 92121, California, 11555, United States

Answer: PersImmune's phone number is 85********

Answer: PersImmune's official website is https://persimmune.com

Answer: PersImmune's revenue is Under $1 Million

Answer: PersImmune's SIC: 8731

Answer: PersImmune's NAICS: 541714

Answer: PersImmune has 1-10 employees

Answer: PersImmune is in Biotechnology

Answer: PersImmune contact info: Phone number: 85******** Website: https://persimmune.com

Answer: PersImmune is a clinical-stage immunotherapy company whose mission is to provide cancer patients with optimized immunotherapy that is personalized on the basis of their own unique tumor signature. Just as no two people are alike, no two cancers are exactly alike; because of this, the same immunotherapy treatment that works for one patient may not work well in another. To address this treatment disparity, PersImmune's proprietary protocol, Personal Adoptive Cellular Therapy for Neoantigens (PACTN) identifies the DNA alterations present in the cancer cells of each patient and generates enriched, tested, highly-specific T-cells that effectively kill the patients tumor cells. These are the patient's own cells, and are not edited or genetically engineered which means patients will experience far less side effects than from chemotherapy or other methods of immunotherapy. Personalized adoptive cellular therapy has the potential to transform the field of cancer treatment by providing safe, highly-tolerable, effective immunotherapy to cancer patients. Personal immunotherapy - because no two patients are exactly alike. PersImmune is currently accepting patients for the Phase 1 clinical trial of its Personalized Adoptive Cell Transfer technology targeting Neoantigens (PACTN). The trial provides a therapy for early and late stage patients of myelodysplastic syndrome (MDS).

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access